Uns models animals desenvolupats per investigadors de l’Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l’Institut Catal\u00e0 d’Oncologia (ICO) han servit per validar l’efic\u00e0cia d’un nou f\u00e0rmac contra el c\u00e0ncer d’ovari resistent al cisplat\u00ed. Es tracta d’un treball multidisciplinari, realitzat en col\u00b7laboraci\u00f3 amb l’empresa biofarmac\u00e8utica Pharmamar, publicat a la revista Clinical Cancer Research.<\/p>\n
El teixit tumoral hum\u00e0 \u00e9s implantat en el mateix \u00f2rgan del ratol\u00ed at\u00edmic del qual procedia. Aquest tipus d’implant, anomenat ortot\u00f2pic, permet reproduir les caracter\u00edstiques histol\u00f2giques, gen\u00e8tiques i epigen\u00e8tiques dels tumors humans, aix\u00ed com reproduir els patrons de disseminaci\u00f3 del tumor, cosa que no s’aconsegueix amb altres m\u00e8todes d’implantaci\u00f3. A m\u00e9s, aquests models tumorals seran claus per al desenvolupament de l’anomenada medicina personalitzada contra diferents tipus de c\u00e0ncer. A part de tumors d’ovari dels investigadors tenen experi\u00e8ncia en la implantaci\u00f3 ortot\u00f2pica d’altres tumors com els de c\u00f2lon, p\u00e0ncrees, mama, endometri o testicle, aix\u00ed com de met\u00e0stasi de fetge i neurofibromatosi. Actualment, estan desenvolupant models de pulm\u00f3 i cap i coll.<\/p>\n
La t\u00e8cnica ha perm\u00e8s comprovar l’efic\u00e0cia de lurbinectedin (PM01183), un medicament aprovat recentment per l’Ag\u00e8ncia d’Aliments i F\u00e0rmacs dels Estats Units (FDA), com “medicament orfe” contra el c\u00e0ncer d’ovari. Aquesta malaltia suposa la cinquena causa de mort entre les dones. L’\u00edndex de superviv\u00e8ncia \u00e9s molt baix perqu\u00e8 sovint es diagnostica en una fase avan\u00e7ada i apareixen resist\u00e8ncies a la quimioter\u00e0pia amb cisplat\u00ed. Per aix\u00f2 es fa necessari trobar tractaments alternatius.<\/p>\n
El lurbinectedin \u00e9s un f\u00e0rmac d’origen mar\u00ed desenvolupat per l’empresa farmac\u00e8utica Pharmamar, del grup Zeltia, que s’ha demostrat efectiu contra tumors d’ovari resistents al cisplat\u00ed en diversos estudis. Un dels m\u00e9s concloents a nivell precl\u00ednic \u00e9s el que s’ha publicat en Clinical Cancer Research. El treball suposa la confirmaci\u00f3 que els implants ortot\u00f2pics en ratolins de laboratori s\u00f3n \u00fatils no nom\u00e9s per aprofundir en el coneixement dels tumors, sin\u00f3 tamb\u00e9 per col\u00b7laborar amb la ind\u00fastria farmac\u00e8utica en el proc\u00e9s de desenvolupament de nous f\u00e0rmacs per tractar el c\u00e0ncer. Recentment el lurbinectedin ha demostrat la seva efic\u00e0cia en un estudi en fase II en el tractament del c\u00e0ncer d’ovari resistent.<\/p>\n
El coordinador del treball i investigador de l’ICO a l\u2019IDIBELL, Alberto Villanueva, destaca la import\u00e0ncia dels models desenvolupats en el seu laboratori que “permeten obtenir tumors crescuts dins de ratolins que mimetitzen les propietats immunohistoqu\u00edmiques, gen\u00e8tiques i epigen\u00e8tiques dels tumors humans, aix\u00ed com la resposta a la quimioter\u00e0pia amb cisplat\u00ed, base del tractament del c\u00e0ncer d’ovari”.<\/p>\n
Refer\u00e8ncia de l’article<\/strong> Uns models animals desenvolupats per investigadors de l’Institut d\u2019Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) i l’Institut Catal\u00e0 d’Oncologia (ICO) han servit per validar l’efic\u00e0cia d’un nou f\u00e0rmac contra el c\u00e0ncer d’ovari resistent al cisplat\u00ed. Es tracta d’un treball multidisciplinari, realitzat en col\u00b7laboraci\u00f3 amb l’empresa biofarmac\u00e8utica Pharmamar, publicat a la revista Clinical Cancer Research. El teixit tumoral […]<\/p>\n","protected":false},"author":6,"featured_media":21006,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[332,375,390,417,447,452,346],"tags":[],"publishpress_future_action":{"enabled":false,"date":"2024-05-10 12:30:54","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9460"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=9460"}],"version-history":[{"count":2,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9460\/revisions"}],"predecessor-version":[{"id":21008,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/9460\/revisions\/21008"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/21006"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=9460"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=9460"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=9460"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nLurbinectedin (PM01183), a New DNA Minor Groove Binder, Inhibits Growth of Orthotopic Primary Graft of Cisplatin-Resistant Epithelial Ovarian Cancer. Vidal A, Munoz C, Guillen MJ, Moreto J, Sara P, Martinez-Iniesta M, Figueras A, Padulles L, Garcia-Rodriguez FJ, Berdiel-Acer M, Pujana MA, Salazar R, Gil-Martin M, Marti L, Ponce J, Mollevi DG, Capella G, Condom E, Vinals F, Huertas D, Cuevas C, Esteller M, Aviles P, Villanueva A. Clin Cancer Res. 2012 Aug 15. [Epub ahead of print]<\/p>\n","protected":false},"excerpt":{"rendered":"